Opus Genetics Q1 Revenue $2.16M, Below Consensus
Reports Q1 revenue $2.16M, consensus $2.93M. "With encouraging momentum across both our LCA5 and BEST1 gene therapy programs, Opus Genetics is entering a defining stretch where we believe our precision targeted approach can reshape what's possible for patients with inherited retinal diseases," said George Magrath, M.D., Chief Executive Officer of Opus Genetics. "Our upcoming BEST1 Cohort 1 clinical data and June R&D Science Forum will provide key opportunities to showcase the depth and maturity of our science and pipeline. Backed by a strong balance sheet and disciplined capital strategy, we are well-positioned to advance our lead programs toward pivotal trials, and accelerate our earlier-stage RDH12, MERTK, and RHO programs into the clinic."
